Medically Reviewed by Brian Koffman, MDCM (retired), MSEd
The U.S. Government Patient Assistance Program will continue to help individuals access Paxlovid for the treatment of COVID-19, especially those who are under-insured and facing high co-pays they are unable to afford based on income.
Learn more about the program by visiting Updates to the Paxlovid U.S. Government Patient Assistance Program for 2025. This assistance applies across government insurance plans (Medicare, Medicaid, Tricare, or Veterans Affairs Community Care Network). The details of what assistance is available vary by coverage, with changes being implemented January 1, 2025 – March 1, 2025.
Research has proven that the risk of dying or having severe problems or even developing long COVID is diminished in the CLL community by the use of Paxlovid. This ASPR (Administration for Strategic Preparedness & Response) program will help ensure that drug cost will not interfere with access in 2025. Pfizer, the manufacturer of Paxlovid, will also continue to offer co-pay assistance for those with commercial insurance.
We encourage any CLL / SLL patients with COVID-19 to discuss with their healthcare team whether Paxlovid is the right choice for them.
While the risks for SARS-COV-2 infections are much lower these days, they are not trivial and having ongoing easy access to Paxlovid is a positive for the CLL community.
